Enliven Therapeutics (NASDAQ:ELVN) Reaches New 52-Week High – Should You Buy?

Enliven Therapeutics, Inc. (NASDAQ:ELVN) shares hit a new 52-week high on Thursday . The stock traded as high as $25.59 and last traded at $23.8930, with a volume of 3714829 shares. The stock had previously closed at $15.47.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on ELVN shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Enliven Therapeutics in a research report on Wednesday, October 8th. Wall Street Zen upgraded shares of Enliven Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, November 15th. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $41.00.

Enliven Therapeutics Trading Up 11.8%

The firm has a market cap of $1.54 billion, a P/E ratio of -14.13 and a beta of 0.41. The stock’s fifty day moving average is $19.07 and its two-hundred day moving average is $19.97.

Enliven Therapeutics (NASDAQ:ELVN) last released its quarterly earnings results on Thursday, November 13th. The company reported ($0.32) EPS for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.11. On average, analysts forecast that Enliven Therapeutics, Inc. will post -1.95 EPS for the current year.

Insider Buying and Selling

In other news, COO Anish Patel sold 6,667 shares of the business’s stock in a transaction dated Friday, November 7th. The stock was sold at an average price of $17.40, for a total transaction of $116,005.80. Following the completion of the transaction, the chief operating officer owned 269,974 shares of the company’s stock, valued at approximately $4,697,547.60. The trade was a 2.41% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Joseph P. Lyssikatos sold 12,500 shares of the company’s stock in a transaction that occurred on Monday, October 20th. The stock was sold at an average price of $22.08, for a total transaction of $276,000.00. Following the completion of the transaction, the insider owned 915,188 shares in the company, valued at approximately $20,207,351.04. This trade represents a 1.35% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 68,330 shares of company stock worth $1,434,762 over the last ninety days. 25.90% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Enliven Therapeutics

Several hedge funds have recently bought and sold shares of the stock. BNP Paribas Financial Markets increased its holdings in shares of Enliven Therapeutics by 33.3% in the 2nd quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company’s stock worth $75,000 after buying an additional 930 shares during the last quarter. Quantbot Technologies LP increased its stake in Enliven Therapeutics by 47.1% in the second quarter. Quantbot Technologies LP now owns 4,477 shares of the company’s stock valued at $90,000 after acquiring an additional 1,434 shares during the last quarter. AlphaQuest LLC purchased a new stake in Enliven Therapeutics during the third quarter valued at about $96,000. Tower Research Capital LLC TRC raised its position in Enliven Therapeutics by 194.3% during the second quarter. Tower Research Capital LLC TRC now owns 5,286 shares of the company’s stock valued at $106,000 after purchasing an additional 3,490 shares in the last quarter. Finally, KLP Kapitalforvaltning AS lifted its stake in Enliven Therapeutics by 58.1% during the second quarter. KLP Kapitalforvaltning AS now owns 6,800 shares of the company’s stock worth $136,000 after purchasing an additional 2,500 shares during the last quarter. 95.08% of the stock is currently owned by institutional investors.

About Enliven Therapeutics

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.